<?xml version="1.0" encoding="UTF-8"?>
<collection xmlns="http://www.loc.gov/MARC21/slim">
 <record>
  <leader>     naa a22        4500</leader>
  <controlfield tag="001">510764592</controlfield>
  <controlfield tag="003">CHVBK</controlfield>
  <controlfield tag="005">20180411083152.0</controlfield>
  <controlfield tag="007">cr unu---uuuuu</controlfield>
  <controlfield tag="008">180411e20131101xx      s     000 0 eng  </controlfield>
  <datafield tag="024" ind1="7" ind2="0">
   <subfield code="a">10.1007/s12094-013-1073-6</subfield>
   <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="035" ind1=" " ind2=" ">
   <subfield code="a">(NATIONALLICENCE)springer-10.1007/s12094-013-1073-6</subfield>
  </datafield>
  <datafield tag="100" ind1="1" ind2=" ">
   <subfield code="a">Gut</subfield>
   <subfield code="D">Ivo</subfield>
   <subfield code="u">Centro Nacional de Análisis Genómico, PCB, C/Baldiri Reixac 4, 08028, Barcelona, Spain</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="245" ind1="1" ind2="0">
   <subfield code="a">New sequencing technologies</subfield>
   <subfield code="h">[Elektronische Daten]</subfield>
   <subfield code="c">[Ivo Gut]</subfield>
  </datafield>
  <datafield tag="520" ind1="3" ind2=" ">
   <subfield code="a">Nucleic acid sequencing is one of the most important tools of biological research with very broad application. Four generations of DNA sequencing technologies can be distinguished by their nature and the kind of output they provide. Sanger sequencing dominated for 30years and was the workhorse of the Human Genome Project. In 2005 the first 2nd generation sequencer was presented with an output orders of magnitude higher than Sanger sequencing and dramatically reduced cost per base. Currently, we are at the dawn of third generation with nanopore systems that are being developed for DNA sequencing. Meanwhile, the field is broadening applications that complement first, second and third generation sequencing systems to get high-resolution genetic information and fourth generation sequencing is on the horizon. Second generation nucleic acid sequencers are systematically applied in many large-scale international projects such as the International Cancer Genome Consortium and the International Human Epigenome Project.</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
   <subfield code="a">Federación de Sociedades Españolas de Oncología (FESEO), 2013</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">DNA</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Sequencing</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Nucleic acid</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="690" ind1=" " ind2="7">
   <subfield code="a">Sequencing technology</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="773" ind1="0" ind2=" ">
   <subfield code="t">Clinical and Translational Oncology</subfield>
   <subfield code="d">Springer Milan</subfield>
   <subfield code="g">15/11(2013-11-01), 879-881</subfield>
   <subfield code="x">1699-048X</subfield>
   <subfield code="q">15:11&lt;879</subfield>
   <subfield code="1">2013</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12094</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2="0">
   <subfield code="u">https://doi.org/10.1007/s12094-013-1073-6</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="908" ind1=" " ind2=" ">
   <subfield code="D">1</subfield>
   <subfield code="a">research-article</subfield>
   <subfield code="2">jats</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">856</subfield>
   <subfield code="E">40</subfield>
   <subfield code="u">https://doi.org/10.1007/s12094-013-1073-6</subfield>
   <subfield code="q">text/html</subfield>
   <subfield code="z">Onlinezugriff via DOI</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">100</subfield>
   <subfield code="E">1-</subfield>
   <subfield code="a">Gut</subfield>
   <subfield code="D">Ivo</subfield>
   <subfield code="u">Centro Nacional de Análisis Genómico, PCB, C/Baldiri Reixac 4, 08028, Barcelona, Spain</subfield>
   <subfield code="4">aut</subfield>
  </datafield>
  <datafield tag="950" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="P">773</subfield>
   <subfield code="E">0-</subfield>
   <subfield code="t">Clinical and Translational Oncology</subfield>
   <subfield code="d">Springer Milan</subfield>
   <subfield code="g">15/11(2013-11-01), 879-881</subfield>
   <subfield code="x">1699-048X</subfield>
   <subfield code="q">15:11&lt;879</subfield>
   <subfield code="1">2013</subfield>
   <subfield code="2">15</subfield>
   <subfield code="o">12094</subfield>
  </datafield>
  <datafield tag="900" ind1=" " ind2="7">
   <subfield code="a">Metadata rights reserved</subfield>
   <subfield code="b">Springer special CC-BY-NC licence</subfield>
   <subfield code="2">nationallicence</subfield>
  </datafield>
  <datafield tag="898" ind1=" " ind2=" ">
   <subfield code="a">BK010053</subfield>
   <subfield code="b">XK010053</subfield>
   <subfield code="c">XK010000</subfield>
  </datafield>
  <datafield tag="949" ind1=" " ind2=" ">
   <subfield code="B">NATIONALLICENCE</subfield>
   <subfield code="F">NATIONALLICENCE</subfield>
   <subfield code="b">NL-springer</subfield>
  </datafield>
 </record>
</collection>
